Novocure Proclaims Favorable Unbiased Knowledge Monitoring Committee Advice to Proceed Section 3 PANOVA-3 Medical Trial of Tumor Treating Fields Remedy in Pancreatic Most cancers

ROOT, Switzerland–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) at the moment introduced the outcomes of a pre-specified interim evaluation for the section 3 PANOVA-3 medical trial evaluating the protection and efficacy of Tumor Treating Fields (TTFields) remedy along with nab-paclitaxel and gemcitabine for the therapy of sufferers with unresectable, regionally superior pancreatic most cancers. An unbiased information monitoring committee (DMC) reviewed the protection and efficacy information for all sufferers within the absolutely enrolled medical trial. The interim evaluation resulted in a DMC suggestion that the medical trial proceed to ultimate evaluation.

“Completion of the interim evaluation with the DMC’s suggestion to proceed PANOVA-3 to completion marks one other vital step in pursuit of our mission to deal with sufferers with tough strong tumors of the stomach,” stated Asaf Danziger, Novocure’s Chief Government Officer. “I want to categorical my due to our sufferers and investigators. We look ahead to reviewing the PANOVA-3 information in 2024 and probably extending the lives of sufferers identified with lethal regionally superior pancreatic most cancers by treating with our novel remedy, Tumor Treating Fields.”

About PANOVA-3

PANOVA-3 is a randomized, open-label medical trial designed to enroll 556 grownup sufferers with unresectable, regionally superior pancreatic adenocarcinoma. Sufferers have been randomized to obtain both the mixture of nab-paclitaxel and gemcitabine concomitant with TTFields remedy tuned to 150 kHz till development or the mixture of nab-paclitaxel and gemcitabine alone. The first endpoint is total survival. Secondary endpoints embrace development free survival, native development free survival, goal response price, one-year survival price, high quality of life, pain-free survival, puncture-free survival, resectability price, and toxicity. Following enrollment of the ultimate affected person in February 2023, sufferers can be adopted for at least 18 months.

About Pancreatic Most cancers

Pancreatic most cancers is among the most deadly cancers and is the third most frequent explanation for loss of life from most cancers within the U.S. Whereas total most cancers incidence and loss of life charges are remaining secure or declining, the incidence and loss of life charges for pancreatic most cancers are growing. It’s estimated that roughly 53,000 sufferers are identified with pancreatic most cancers annually within the U.S. Pancreatic most cancers has a five-year relative survival price of simply 10%.

Physicians use completely different combos of surgical procedure, radiation and pharmacological therapies to deal with pancreatic most cancers, relying on the stage of the illness. For sufferers with regionally superior pancreatic most cancers involving encasement of arteries however no extra-pancreatic illness, the usual of care is surgical procedure adopted by chemotherapy with or with out radiation. Sadly, nearly all of regionally superior circumstances are identified as soon as the most cancers is not operable, typically leaving chemotherapy with or with out radiation as the one therapy choice.

About Tumor Treating Fields Remedy

Tumor Treating Fields (TTFields) are electrical fields that exert bodily forces to kill most cancers cells through a wide range of mechanisms. TTFields don’t considerably have an effect on wholesome cells as a result of they’ve completely different properties (together with division price, morphology, and electrical properties) than most cancers cells. The a number of, distinct mechanisms of TTFields remedy work collectively to selectively goal and kill most cancers cells. As a result of its multimechanistic actions, TTFields remedy could be added to most cancers therapy modalities in accredited indications and demonstrates enhanced results throughout strong tumor varieties when used with chemotherapy, radiotherapy, immune checkpoint inhibition, or PARP inhibition in preclinical fashions. TTFields remedy gives medical versatility that has the potential to assist tackle therapy challenges throughout a variety of strong tumors. To be taught extra about Tumor Treating Fields remedy and its multifaceted impact on most cancers cells, go to

About Novocure

Novocure is a world oncology firm working to increase survival in among the most aggressive types of most cancers by the event and commercialization of its progressive remedy, Tumor Treating Fields. Novocure’s commercialized merchandise are accredited in sure nations for the therapy of grownup sufferers with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. Novocure has ongoing or accomplished medical research investigating Tumor Treating Fields in mind metastases, gastric most cancers, glioblastoma, liver most cancers, non-small cell lung most cancers, pancreatic most cancers and ovarian most cancers.

Headquartered in Root, Switzerland and with a rising international footprint, Novocure has regional working facilities in Portsmouth, New Hampshire and Tokyo, in addition to a analysis heart in Haifa, Israel. For extra details about the corporate, please go to and comply with @Novocure on LinkedIn and Twitter.

Ahead-Trying Statements

Along with historic details or statements of present situation, this press launch might comprise forward-looking statements. Ahead-looking statements present Novocure’s present expectations or forecasts of future occasions. These might embrace statements relating to anticipated scientific progress on its analysis applications, medical examine progress, growth of potential merchandise, interpretation of medical outcomes, prospects for regulatory approval, manufacturing growth and capabilities, market prospects for its merchandise, protection, collections from third-party payers and different statements relating to issues that aren’t historic details. You could establish a few of these forward-looking statements by means of phrases within the statements similar to “anticipate,” “estimate,” “anticipate,” “mission,” “intend,” “plan,” “imagine” or different phrases and phrases of comparable that means. Novocure’s efficiency and monetary outcomes might differ materially from these mirrored in these forward-looking statements attributable to common monetary, financial, environmental, regulatory and political circumstances in addition to points arising from the COVID-19 pandemic and different extra particular dangers and uncertainties dealing with Novocure similar to these set forth in its Annual Report on Kind 10-Ok filed on February 23, 2023, and subsequent filings with the U.S. Securities and Trade Fee. Given these dangers and uncertainties, all or any of those forward-looking statements might show to be incorrect. Due to this fact, you shouldn’t depend on any such elements or forward-looking statements. Moreover, Novocure doesn’t intend to replace publicly any forward-looking assertion, besides as required by regulation. Any forward-looking statements herein converse solely as of the date hereof. The Non-public Securities Litigation Reform Act of 1995 permits this dialogue.

Related Articles

Back to top button